1. FGF21 Response Varies by Sugar Type and is Associated with Body Weight, Dietary Added Sugar, and Neural Signaling in Humans
- Author
-
Brendan Angelo, Alexis DeFendis, Alexandra G. Yunker, Kay Jann, Kathleen A. Page, Trevor A. Pickering, Shan Luo, Monterosso, and Jasmin M Alves
- Subjects
medicine.medical_specialty ,Sucrose ,FGF21 ,media_common.quotation_subject ,Appetite ,Added sugar ,Biology ,Overweight ,medicine.disease ,Obesity ,Energy homeostasis ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Internal medicine ,medicine ,medicine.symptom ,Sugar ,media_common - Abstract
Fibroblast growth factor 21 (FGF21) is a liver-derived hormone that regulates energy homeostasis. In humans, few studies have investigated whether FGF21 may act to suppress sugar intake and influence eating behavior, and the effects of adiposity on post-ingestive FGF21 regulation of appetite are unknown. Here, we demonstrate among two cohorts of healthy, young adults that acute oral fructose and sucrose compared to glucose lead to greater circulating FGF21. Moreover, high compared to low dietary added sugar intake is associated with greater sucrose-stimulated FGF21 among participants with healthy weight but attenuated in people with overweight and obesity. In addition, our study is the first to demonstrate associations between circulating FGF21 and neural signaling following an acute sucrose load among humans with healthy weight. Collectively, our results suggest that these potential compensatory relationships between sucrose-stimulated circulating FGF21, habitual sugar intake, and post-ingestive brain responses may be altered among adults with overweight and obesity.Significance StatementAnimal models have established FGF21 as an autoregulator of sweet consumption, but few studies have examined post-ingestive FGF21 effects in humans. In this report, we demonstrate a compensatory relationship between sucrose-stimulated FGF21 and high dietary added sugar intake through a potential liver-to-brain negative-feedback cycle among healthy, young adults. Notably, our findings also suggest that humans with overweight and obesity may have altered FGF21 neuroendocrine signaling.
- Published
- 2021